Literature DB >> 23636924

Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events.

Ki Park1, Anthony A Bavry.   

Abstract

Aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease. However, its benefit in patients without a history of cardiovascular disease is not as clear, particularly in people with diabetes, in women, and in the elderly. Recent studies have provided insight into the risks of aspirin use, particularly bleeding, compared with its benefits in these subgroups.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636924     DOI: 10.3949/ccjm.80a.12146

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  5 in total

1.  Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.

Authors:  Anthony A Bavry; Islam Y Elgendy; Yedid Elbez; Ahmed N Mahmoud; Emmanuel Sorbets; Philippe Gabriel Steg; Deepak L Bhatt
Journal:  Clin Cardiol       Date:  2017-05-18       Impact factor: 2.882

2.  Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012).

Authors:  Jing Fang; Mary G George; Renee M Gindi; Yuling Hong; Quanhe Yang; Carma Ayala; Brian W Ward; Fleetwood Loustalot
Journal:  Am J Cardiol       Date:  2015-01-14       Impact factor: 2.778

3.  Preventive Aspirin and Other Antiplatelet Medication Use Among U.S. Adults Aged ≥ 40 Years: Data from the National Health and Nutrition Examination Survey, 2011-2012.

Authors:  Qiuping Gu; Charles F Dillon; Mark S Eberhardt; Jacqueline D Wright; Vicki L Burt
Journal:  Public Health Rep       Date:  2015 Nov-Dec       Impact factor: 2.792

4.  Aspirin delimits platelet life span by proteasomal inhibition.

Authors:  Manasa K Nayak; Ayusman Dash; Nitesh Singh; Debabrata Dash
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

Review 5.  Aspirin for primary prevention of cardiovascular disease.

Authors:  Jobert Richie N Nansseu; Jean Jacques N Noubiap
Journal:  Thromb J       Date:  2015-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.